Baidu
map

Eur Respir J:囊性纤维化患儿肺部疾病进展的危险因素!

2018-06-09 xing.T MedSci原创

在对荷兰CF儿童随访5年后,研究人员能够确定未来肺功能恶化的几个危险因素。特别是,PPI使用与肺部疾病进展之间的关联,其需要进一步的研究。

为了确定囊性纤维化(CF)患儿肺部疾病进展的潜在危险因素,近日,呼吸疾病领域权威杂志Eur Respir J上发表了一篇研究文章,研究人员分析了所有在荷兰CF登记中心(2009-2014)注册的CF儿童(年龄≥5岁)的纵向数据。

肺疾病进展表现为肺功能下降(1秒呼气末用力呼气量(FEV1)%pred)和肺部恶化率。基线的潜在危险因素包括性别、年龄、最佳FEV1%pred、最大用力肺活量%pred、基因型、体重指数Z-评分、胰腺功能不全、药物使用(质子泵抑制剂(PPI)、预防抗生素和吸入性糖皮质激素)、CF相关糖尿病、变应性支气管肺曲菌病和铜绿假单胞菌定植。

研究人员对545例儿童的资料进行了分析。PPI的使用与每年的FEV1%pred下降(P=0.017)和未来的肺恶化率(P=0.006)相关。此外,基线较低的FEV1%pred(P=0.007)、预防性吸入抗生素治疗(P=0.006)和基线年肺功能恶化加重(P=0.002)与随后几年的肺功能恶化加重有关。

在对荷兰CF儿童随访5年后,研究人员能够确定未来肺功能恶化的几个危险因素。特别是,PPI使用与肺部疾病进展之间的关联,其需要进一步的研究。

原始出处:

Marieke van Horck,et al. Risk factors for lung disease progression in children with cystic fibrosis. Eur Respir J. 2018. http://erj.ersjournals.com/content/51/6/1702509

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1675867, encodeId=faf516e5867ca, content=<a href='/topic/show?id=7395403e580' target=_blank style='color:#2F92EE;'>#囊性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40375, encryptionId=7395403e580, topicName=囊性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=926927300775, createdName=wolongzxh, createdTime=Tue Nov 27 13:41:00 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907700, encodeId=5db1190e70092, content=<a href='/topic/show?id=fdcee0731d2' target=_blank style='color:#2F92EE;'>#疾病进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70731, encryptionId=fdcee0731d2, topicName=疾病进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Sat Jul 28 21:41:00 CST 2018, time=2018-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=324379, encodeId=c1f03243e9f7, content=很好很好.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Fri Jun 15 09:20:15 CST 2018, time=2018-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542305, encodeId=65c715423050a, content=<a href='/topic/show?id=ab8d8235654' target=_blank style='color:#2F92EE;'>#肺部疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82356, encryptionId=ab8d8235654, topicName=肺部疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f7613405394, createdName=1249857fm36暂无昵称, createdTime=Mon Jun 11 01:41:00 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322786, encodeId=e60f322e86d9, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sat Jun 09 11:19:30 CST 2018, time=2018-06-09, status=1, ipAttribution=)]
    2018-11-27 wolongzxh
  2. [GetPortalCommentsPageByObjectIdResponse(id=1675867, encodeId=faf516e5867ca, content=<a href='/topic/show?id=7395403e580' target=_blank style='color:#2F92EE;'>#囊性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40375, encryptionId=7395403e580, topicName=囊性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=926927300775, createdName=wolongzxh, createdTime=Tue Nov 27 13:41:00 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907700, encodeId=5db1190e70092, content=<a href='/topic/show?id=fdcee0731d2' target=_blank style='color:#2F92EE;'>#疾病进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70731, encryptionId=fdcee0731d2, topicName=疾病进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Sat Jul 28 21:41:00 CST 2018, time=2018-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=324379, encodeId=c1f03243e9f7, content=很好很好.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Fri Jun 15 09:20:15 CST 2018, time=2018-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542305, encodeId=65c715423050a, content=<a href='/topic/show?id=ab8d8235654' target=_blank style='color:#2F92EE;'>#肺部疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82356, encryptionId=ab8d8235654, topicName=肺部疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f7613405394, createdName=1249857fm36暂无昵称, createdTime=Mon Jun 11 01:41:00 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322786, encodeId=e60f322e86d9, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sat Jun 09 11:19:30 CST 2018, time=2018-06-09, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1675867, encodeId=faf516e5867ca, content=<a href='/topic/show?id=7395403e580' target=_blank style='color:#2F92EE;'>#囊性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40375, encryptionId=7395403e580, topicName=囊性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=926927300775, createdName=wolongzxh, createdTime=Tue Nov 27 13:41:00 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907700, encodeId=5db1190e70092, content=<a href='/topic/show?id=fdcee0731d2' target=_blank style='color:#2F92EE;'>#疾病进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70731, encryptionId=fdcee0731d2, topicName=疾病进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Sat Jul 28 21:41:00 CST 2018, time=2018-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=324379, encodeId=c1f03243e9f7, content=很好很好.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Fri Jun 15 09:20:15 CST 2018, time=2018-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542305, encodeId=65c715423050a, content=<a href='/topic/show?id=ab8d8235654' target=_blank style='color:#2F92EE;'>#肺部疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82356, encryptionId=ab8d8235654, topicName=肺部疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f7613405394, createdName=1249857fm36暂无昵称, createdTime=Mon Jun 11 01:41:00 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322786, encodeId=e60f322e86d9, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sat Jun 09 11:19:30 CST 2018, time=2018-06-09, status=1, ipAttribution=)]
    2018-06-15 phoebeyan520

    很好很好.学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1675867, encodeId=faf516e5867ca, content=<a href='/topic/show?id=7395403e580' target=_blank style='color:#2F92EE;'>#囊性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40375, encryptionId=7395403e580, topicName=囊性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=926927300775, createdName=wolongzxh, createdTime=Tue Nov 27 13:41:00 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907700, encodeId=5db1190e70092, content=<a href='/topic/show?id=fdcee0731d2' target=_blank style='color:#2F92EE;'>#疾病进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70731, encryptionId=fdcee0731d2, topicName=疾病进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Sat Jul 28 21:41:00 CST 2018, time=2018-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=324379, encodeId=c1f03243e9f7, content=很好很好.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Fri Jun 15 09:20:15 CST 2018, time=2018-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542305, encodeId=65c715423050a, content=<a href='/topic/show?id=ab8d8235654' target=_blank style='color:#2F92EE;'>#肺部疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82356, encryptionId=ab8d8235654, topicName=肺部疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f7613405394, createdName=1249857fm36暂无昵称, createdTime=Mon Jun 11 01:41:00 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322786, encodeId=e60f322e86d9, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sat Jun 09 11:19:30 CST 2018, time=2018-06-09, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1675867, encodeId=faf516e5867ca, content=<a href='/topic/show?id=7395403e580' target=_blank style='color:#2F92EE;'>#囊性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40375, encryptionId=7395403e580, topicName=囊性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=926927300775, createdName=wolongzxh, createdTime=Tue Nov 27 13:41:00 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907700, encodeId=5db1190e70092, content=<a href='/topic/show?id=fdcee0731d2' target=_blank style='color:#2F92EE;'>#疾病进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70731, encryptionId=fdcee0731d2, topicName=疾病进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Sat Jul 28 21:41:00 CST 2018, time=2018-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=324379, encodeId=c1f03243e9f7, content=很好很好.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Fri Jun 15 09:20:15 CST 2018, time=2018-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542305, encodeId=65c715423050a, content=<a href='/topic/show?id=ab8d8235654' target=_blank style='color:#2F92EE;'>#肺部疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82356, encryptionId=ab8d8235654, topicName=肺部疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f7613405394, createdName=1249857fm36暂无昵称, createdTime=Mon Jun 11 01:41:00 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=322786, encodeId=e60f322e86d9, content=学习了谢谢分享!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200816/e4675a86ea694f12b82202b320dc2654/12f6b900498349e994ce8f516a584d6a.jpg, createdBy=09431951290, createdName=大爰, createdTime=Sat Jun 09 11:19:30 CST 2018, time=2018-06-09, status=1, ipAttribution=)]
    2018-06-09 大爰

    学习了谢谢分享!!

    0

相关资讯

Diabetes Care:胰岛白细胞介素-1β免疫反应性是囊性纤维化的早期特征!

这些发现揭示了CF患者潜在胰岛病理新的分子途径和治疗靶点,可能在开发CFRD新治疗方法上具有重要的价值。

儿童囊性纤维化影像学表现2例报告与临床分析

囊性纤维化(Cysticfibrosis,CF)是欧美白种人最常见的致死性常染色体隐性遗传病,而亚洲人和非洲人少见。国内只有少数报道,影像学表现报道就更罕见。本文报道2例临床确诊CF病例的影像学表现,并结合文献对CF临床及影像诊断提出一点经验,旨在提高对本病的诊断水平。

NEJM:新生儿囊性纤维化胎粪性肠梗阻-病例报道

胎粪性肠梗阻,可能是囊性纤维化的早期表现,也可发生于极低出生体重早产儿。肠梗阻是浓缩的胎粪在回肠腔内积累的结果。对胎粪延迟排出的鉴别诊断包括先天性巨结肠和胎粪栓综合征。

囊性纤维化:抗生素相关性肾损伤的检测

遗传性疾病囊性纤维化(CF)的特征是继发性细菌性肺部感染,常由特定的耐药细菌铜绿假单胞菌所致。而氨基糖苷类抗生素对这种细菌具有良好的作用,常被用于治疗这些感染。但是,氨基糖苷类抗生素可能会损害肾脏。尽管有降低风险的策略,但氨基糖苷类抗生素的暴露与囊性纤维化患儿的急性肾损伤(AKI)密切相关。

Lancet Diabetes Endocrinol:囊性纤维化新诊断糖尿病患者,瑞格列奈vs胰岛素

2018年2月,发表在《Lancet Diabetes Endocrinol》的一项由德国、法国和意大利科学家进行的多中心、开放标签、随机试验,考察了瑞格列奈vs胰岛素治疗囊性纤维化新诊断糖尿病患者的有效性和安全性。

Lancet respir med:依法卡托可用于1-2岁囊性纤维化患儿,疗效好、安全性高

注释:囊性纤维化是一种遗传性外分泌腺疾病,主要影响胃肠道和呼吸系统,通常具有慢性梗阻性肺部病变、胰腺外分泌功能不良和汗液电解质异常升高的特征。Ivacaftor(依法卡托)对于2岁及以上的携带特异性CFTR突变的囊性纤维化患儿一般是安全有效的。依法卡托是否可用于2岁以下的患儿尚无明确数据,现研究人员对依法卡托用于1-2岁的携带特异性CFTR突变的囊性纤维化患儿的疗效和安全性进行评估。研究人员进行一

Baidu
map
Baidu
map
Baidu
map